The i31-SLNB Identifies Patients with Cutaneous Melanoma Who Have Less than 5% Risk of SLN Positivity while the CP-GEP does not. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 2, p. s563, 2025. DOI: 10.25251/skin.10.supp.563. Disponível em: https://skin.dermsquared.com/skin/article/view/3289. Acesso em: 17 apr. 2026.